DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: Community Center
Online groups, photo galleries and blogs
3 Gene Editing Approaches for Sickle Cell Disease
Sickle cell disease (SCD) is a perfect candidate for gene editing. It is perhaps the best understood single-gene condition, due to a substitution of a single DNA base in the gene that encodes the beta subunit of hemoglobin, the protein that carries oxygen in the blood.
Red blood cells, which bend into the sickle shape in the disease, obstructing circulation and causing excruciating pain, descend from hematopoietic (“blood-forming”) stem cells (HSCs) in the bone marrow. So theoretically, a patient’s stem cells can be removed, the mutation replaced in them, and then the fixed cells infused back into the patient, circumventing an immune response.
+myBinderRelated Content
-
education & researchGenetic treatment of a molecular disorder: gene therapy approaches to sickle cell diseaseEffective medical management for sickle ...
-
Community CenterToday’s Faces of Sickle Cell Disease: Rodrick MurrayRodrick Murray was 3 months old when he ...
-
education & researchFentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Si...BACKGROUND: Sickle cell disease (SCD) is...
-
news & eventsFirst Sickle Cell Patient Dosed in Phase 2a of IMR-687This morning, Imara Inc. announced that ...
-
news & eventsLab-Grown Blood: What Is It, and How Could It Be Useful?Sometimes a person may have a blood diso...
-
news & eventsNovartis acquires US pharma research firm Selexys PharmaceuticalsSwiss-based pharmaceuticals giant Novart...
-
Community CenterSuccessful Gene Therapy for Sickle Cell DiseasePrior to this report, the only curative ...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.